Literature DB >> 24419120

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

Rita Chiari1, Simona Duranti, Vienna Ludovini, Guido Bellezza, Anjuta Pireddu, Vincenzo Minotti, Chiara Bennati, Lucio Crinò.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419120     DOI： 10.1200/JCO.2012.47.7141

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.

Authors:  F Koinis; A Voutsina; A Kalikaki; A Koutsopoulos; E Lagoudaki; E Tsakalaki; E K Dermitzaki; E Kontopodis; A G Pallis; V Georgoulias; A Kotsakis
Journal:  Clin Transl Oncol       Date:  2017-06-19       Impact factor: 3.405

2.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

Authors:  Weijing Cai; Dongmei Lin; Chunyan Wu; Xuefei Li; Chao Zhao; Limou Zheng; Shannon Chuai; Ke Fei; Caicun Zhou; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2015-09-28       Impact factor: 44.544

3.  Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.

Authors:  Jiandong Wang; Qin Shen; Qunli Shi; Bo Yu; Xuan Wang; Kai Cheng; Guangming Lu; Xiaojun Zhou
Journal:  J Exp Clin Cancer Res       Date:  2014-12-21

4.  Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Authors:  Jianya Zhou; Jing Zheng; Jing Zhao; Yihong Sheng; Wei Ding; Jianying Zhou
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

5.  Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.

Authors:  Ying-Sheng Wen; Ling Cai; Xue-Wen Zhang; Jian-Fei Zhu; Zi-Chen Zhang; Jian-Yong Shao; Lan-Jun Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

6.  Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

Authors:  Yuping Li; Shanshan Su; Guoping Cai; Quan Lin; Ying Zhou; Jinsheng Ouyang; Bicheng Chen; Junru Ye; Xiuling Wu; Chengshui Chen
Journal:  Mol Clin Oncol       Date:  2017-06-29

Review 7.  Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Authors:  Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino
Journal:  Oncotarget       Date:  2017-04-26

8.  Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis.

Authors:  Chenyang Ye; Ji Wang; Shu Zheng; Ying Chai
Journal:  Onco Targets Ther       Date:  2016-10-26       Impact factor: 4.147

Review 9.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Authors:  Mingxiang Ye; Xinxin Zhang; Nan Li; Yong Zhang; Pengyu Jing; Ning Chang; Jianxiong Wu; Xinling Ren; Jian Zhang
Journal:  Oncotarget       Date:  2016-03-15

10.  Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.

Authors:  Wei Ma; Lei Guo; Ling Shan; Xiuyun Liu; Ning Lyu; Jianming Ying
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.